Eladocagene exuparvovec. HTA ID: 22072

Assessment Status
HTA ID 22072
Drug Eladocagene exuparvovec
Brand Upstaza®
Indication For the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype.
Assessment Process
Rapid review commissioned 08/12/2022
Rapid review completed 23/12/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of eladocagene exuparvovec compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/02/2023
Pre-submission consultation with Applicant 18/04/2023

Not considered cost-effective due to non-submission of full HTA.